The association of<i>FOXP3</i>gene polymorphisms with cancer susceptibility: a comprehensive systemic review and meta-analysisYan Chen, Xia Zhao, Xiaoxue Qi et al.|Bioscience Reports|2019Cited by 12
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancerJung‐Yun Lee, Lingying Wu, Jeong‐Won Lee et al.|Gynecologic Oncology|2025Cited by 7